Cancer patients frequently present with multiple comorbid conditions that complicate therapeutic decision-making and increase the risk of medication-related problems (MRPs). This prospective interventional study, conducted over six months at a tertiary oncology center, evaluated the prevalence of comorbidities, identified and classified MRPs, assessed drug–drug interactions (DDIs), and documented pharmacist interventions in 251 cancer patients receiving active treatment. Cardiovascular (35.8%) and endocrine disorders (33.4%) were the most common comorbidities, with hypertension (33.4%) and diabetes mellitus (31.4%) being predominant. A total of 267 MRPs were identified, of which DDIs constituted the largest proportion (65.1%), followed by adverse drug reactions (12.7%) and failure to receive medications (11.9%). Among the 174 DDIs detected, 39% were major and 44% were moderate in severity, commonly involving combinations of anticancer agents or interactions between chemotherapy, premedications, and comorbidity drugs. Clinical pharmacists made 130 documented interventions, most of which were moderate in significance and focused on patient counseling, adherence improvement, therapy re-initiation, and monitoring recommendations. The findings highlight a substantial burden of polypharmacy, clinically significant DDIs, and adverse events among cancer patients with coexisting diseases. The study emphasizes the critical role of clinical pharmacists in minimizing MRPs, enhancing patient safety, and optimizing therapeutic outcomes in oncology care.
Keywords: N/A
How to cite this article: Donepudi V, Subhash K, Philipose R, Reddy CH, Patel H, Parthasarathi G, Evaluation of Medication-Related Problems and Drug–Drug Interactions in Cancer Patients with Co-morbidities. Int J Drug Deliv Technol. 2026;16(4s): 53-58; DOI: 10.25258/ijddt.16.53-58